Abstract
AbstractSaralasin is the only marketed member of a class of compounds described as angiotensin II receptor antagonists. Its pharmacology is characterized by three general properties: (1) no actions unrelated to the renin‐angiotensin system; (2) a small partial agonist effect in some tissues in vitro and in some animal models in vivo, and (3) a blood‐pressure lowering response to saralasin evident only in animals with an activated endogenous renin angiotensin system. It is suggested that the natriuretic effect of angiotensin II mediated via central nervous system (CNS) mechanisms may be future productive area of research in which to study the actions of angiotensin II antagonists.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
